SCHEMBL26175116

SCHEMBL26175116

CN1CCC(n2cc(NC(=O)c3cnc4[nH]cc(-c5cc6ccncc6s5)c4c3)cn2)CC1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPK7 Q13164 1/20 0.45
▸ DYRK1A Q13627 14/20 0.42
▸ GSK3B P49841 6/20 0.42
▸ CLK2 P49760 6/20 0.42
▸ CLK3 P49761 5/20 0.42
▸ ROCK2 O75116 1/20 0.39
▸ ROCK1 Q13464 1/20 0.39
▸ WNT1 P04628 2/20 0.39
▸ LRRK2 Q5S007 1/20 0.39
▸ CLK1 P49759 2/20 0.39
▸ DYRK1B Q9Y463 1/20 0.39
▸ MELK Q14680 1/20 0.38
▸ PAK1 Q13153 1/20 0.38
▸ NTRK1 P04629 1/20 0.38
▸ FLT3 P36888 1/20 0.38
▸ NTRK3 Q16288 1/20 0.38
▸ NTRK2 Q16620 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26175077 0.91 MAPK7 (0.43) MAPK7DYRK1AGSK3BCLK1DYRK1B
SCHEMBL26174909 0.84 HPGDS (0.41) DYRK1AROCK2WNT1DYRK1BNTRK1
SCHEMBL30400148 0.81 DYRK1A (0.48) DYRK1AGSK3BCLK2CLK3WNT1
SCHEMBL26175197 0.81 DYRK1A (0.48) DYRK1AGSK3BCLK2CLK3WNT1
SCHEMBL26174995 0.80 DYRK1A (0.35) DYRK1AGSK3BCLK1DYRK1BNTRK1
SCHEMBL30400780 0.79 MAPK7 (0.49) MAPK7DYRK1AGSK3BCLK2CLK3
SCHEMBL26175149 0.79 MAPK7 (0.49) MAPK7DYRK1AGSK3BCLK2CLK3
SCHEMBL26177028 0.79 ABL1 (0.43) DYRK1AGSK3BWNT1CLK1NTRK1
SCHEMBL30398632 0.79 DYRK1A (0.48) MAPK7DYRK1AGSK3BCLK2CLK3
SCHEMBL30398955 0.79 FLT3 (0.48) MAPK7DYRK1AGSK3BCLK2CLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4415817-A1 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 — — EP claimed
WO-2023064349-A1 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO claimed
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2023-06-22 — — US disclosed
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2023-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 MAPK7 532/4885DYRK1A 1/4885GSK3B 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback